Dung T. Le, MD, on Noncolorectal GI Cancers: Results From a Phase II Study of Pembrolizumab
2016 Gastrointestinal Cancers SymposiumDung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, reports findings on this agent, which showed promising activity in patients with previously treated progressive, advanced cancer (Abstract 195).
Related Videos
Eric Francois, MD, on Rectal Cancer: Findings From the ACCORD12 Trial (French Language Version)
Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses in French the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract ...
Somnath Mukherjee, MD, on Esophageal Adenocarcinoma: Results of the NEOSCOPE Trial
Somnath Mukherjee, MD, of Oxford University, discusses this phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine- or paclitaxel/carboplatin-based ch...
Eric Francois, MD, on Rectal Cancer: Findings From the ACCORD12 Trial
Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490). To v...
Toshihiko Doi, MD, PhD, on Esophageal Carcinoma: Study Results From KEYNOTE-028
Toshihiko Doi, MD, PhD, of Japan’s National Cancer Center Hospital East, discusses updated results on pembrolizumab for advanced esophageal cancer (Abstract 7).
Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial
Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive...
